XML 34 R23.htm IDEA: XBRL DOCUMENT v3.6.0.2
Organization and Significant Accounting Policies - Additional Information (Detail) - USD ($)
3 Months Ended
Nov. 18, 2016
Dec. 31, 2016
Dec. 31, 2015
Nov. 29, 2016
Sep. 30, 2016
Sep. 30, 2015
Schedule Of Investments [Line Items]            
Percentage of workforce reduced due to discontinued clinical program       30.00%    
Cash and cash equivalents   $ 102,105,569 $ 62,165,088   $ 85,366,448 $ 81,214,354
Net increase (decrease) in cash   16,739,121 $ (19,049,266)      
Proceeds from the issuance of common stock   12,500,000        
Restricted Cash   0     0  
Investments   0     0  
Fair value of contingent consideration obligation due to discontinuation of clinical trials   0     $ 0  
Maximum            
Schedule Of Investments [Line Items]            
Amount insured in FDIC per account   $ 250,000        
Property, Plant and Equipment, Useful Life   7 years        
Minimum            
Schedule Of Investments [Line Items]            
Property, Plant and Equipment, Useful Life   3 years        
Amgen            
Schedule Of Investments [Line Items]            
Proceeds from upfront payments and equity investments   $ 42,500,000        
Amgen | Common Stock Purchase Agreement            
Schedule Of Investments [Line Items]            
Proceeds from the issuance of common stock $ 12,500,000          
Amgen | ARO-LPA Agreement            
Schedule Of Investments [Line Items]            
Common stock issued 1,745,810          
Upfront payment $ 30,000,000          
Amgen | ARO-LPA Agreement | Common Stock Purchase Agreement            
Schedule Of Investments [Line Items]            
Common stock issued 1,745,810